Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 28% Improvement Relative Risk Hospitalization 24% Progression 18% c19early.org/pl Wan et al. Paxlovid for COVID-19 LATE TREATMENT Is late treatment with paxlovid beneficial for COVID-19? Retrospective 23,887 patients in China (February - September 2022) Lower mortality (p<0.0001) and hospitalization (p<0.0001) Wan et al., J. Infection, doi:10.1016/j.jinf.2023.02.029 Favors paxlovid Favors control
Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase
Wan et al., Journal of Infection, doi:10.1016/j.jinf.2023.02.029
Wan et al., Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase, Journal of Infection, doi:10.1016/j.jinf.2023.02.029
Feb 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 30,040 hospitalized patients in Hong Kong, showing lower mortality with paxlovid treatment. Patients with contraindications to paxlovid were not excluded.
[Hoertel] find that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
risk of death, 28.0% lower, HR 0.72, p < 0.001, treatment 541 of 6,604 (8.2%), control 2,541 of 17,283 (14.7%), adjusted per study, multivariable, Cox proportional hazards.
risk of hospitalization, 24.0% lower, HR 0.76, p < 0.001, treatment 1,772 of 6,604 (26.8%), control 2,541 of 17,283 (14.7%), adjusted per study, multivariable, Cox proportional hazards.
risk of progression, 18.0% lower, HR 0.82, p < 0.001, treatment 1,816 of 6,604 (27.5%), control 2,541 of 17,283 (14.7%), adjusted per study, A&E admission, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wan et al., 22 Feb 2023, retrospective, China, peer-reviewed, 13 authors, study period 26 February, 2022 - 30 September, 2022.
Contact: ewchan@hku.hk, wongick@hku.hk.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Abstract: Journal Pre-proof Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phaseRunning title: Survival benefits of COVID-19 oral antiviral drugs Eric Yuk Fai Wan Boyuan Wang Sukriti Mathur Cheyenne I Ying Chan Vincent Ka Chun Yan Francisco Tsz Tsun Lai Celine Sze Ling Chui Xue Li Carlos King Ho Wong Philip Hei Li Chak Sing Lau Ian Chi Kei Wong Esther Wai Yin Chan PII: S0163-4453(23)00117-2 DOI: https://doi.org/10.1016/j.jinf.2023.02.029 Reference: YJINF5894 To appear in: Journal of Infection Accepted date: 18 Please cite this article as: Eric Yuk Fai Wan, Boyuan Wang, Sukriti Mathur, Cheyenne I Ying Chan, Vincent Ka Chun Yan, Francisco Tsz Tsun Lai, Celine Sze Ling Chui, Xue Li, Carlos King Ho Wong, Philip Hei Li, Chak Sing Lau, Ian Chi Kei Wong and Esther Wai Yin Chan, Molnupiravir and nirmatrelvirritonavir reduce mortality risk during post-acute COVID-19 phaseRunning title: Survival benefits of COVID-19 oral antiviral drugs, Journal of Infection, () doi:https://doi.org/10.1016/j.jinf.2023.02.029 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © Published by Elsevier. Title: Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase Authors: Eric Yuk Fai Wan, PhD1,2,3†; Boyuan Wang, MPH3†, Sukriti Mathur, BSc3†, Cheyenne I Ying Chan, MPsyMed3, Vincent Ka Chun Yan, BPharm1; Francisco Tsz Tsun Lai, PhD1,2; Celine Sze Ling Chui, PhD2,4,5; Xue Li, PhD1,2,6; Carlos King Ho Wong, PhD1,2,3; Philip oo f Hei Li, MBBS6; Chak Sing Lau, MD6; Ian Chi Kei Wong, PhD1,2,7,8*, Esther Wai Yin Chan, PhD1,2,7,9* Centre for Safe Medication Practice and research, Department of Pharmacology and e- 1 pr Affiliations: Pr Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong China Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, 3 ur n Hong Kong China al 2 Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong China School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Jo 4 Kong China 5 School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong China 6 Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong China 7 Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China 1 8 Aston Pharmacy School, Aston University, Birmingham, B4 7ET, UK 9 The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen, China † Co-first authors and contributed equally oo Running title: Survival benefits of COVID-19 oral antiviral drugs f * Co-Corresponding authors pr Correspondence Dr Esther W. Chan, PhD e- Associate Professor, Department of Pharmacology and Pharmacy Pr Research Lead, Centre for Safe..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit